Alnylam Makes Entry Into Chinese RNAi Market
This article was originally published in PharmAsia News
Executive Summary
Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm
You may also be interested in...
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 1 of 2)
OSONG, Korea - As big pharma continues snatching up biotechs in its quest to fill drying pipelines, very few biotechs will be left standing in 2013, Merck exec Greg Wiederrecht told Bio Korea attendees Oct. 8.
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 1 of 2)
OSONG, Korea - As big pharma continues snatching up biotechs in its quest to fill drying pipelines, very few biotechs will be left standing in 2013, Merck exec Greg Wiederrecht told Bio Korea attendees Oct. 8.
Yangtze Delta Expected To Be Largest CRO Cluster By 2015
SUZHOU, China - China's Yangtze delta, which includes Shanghai, Suzhou, Nanjing and Hangzhou, will be the largest CRO cluster in the world by 2015 and Shanghai will be the number one city in the world by number of scientists engaged in commercial drug discovery, Kewen Jin, GM of Charles River China, said during the BioBay Investor Forum in Suzhou Aug. 28